632,131 Shares in Gain Therapeutics, Inc. $GANX Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP purchased a new stake in shares of Gain Therapeutics, Inc. (NASDAQ:GANX) in the second quarter, Holdings Channel.com reports. The fund purchased 632,131 shares of the company’s stock, valued at approximately $1,283,000.

Several other institutional investors have also recently bought and sold shares of the business. Potomac Capital Management Inc. acquired a new position in Gain Therapeutics in the fourth quarter worth $3,252,000. JPMorgan Chase & Co. acquired a new stake in shares of Gain Therapeutics in the third quarter valued at $47,000. Geode Capital Management LLC increased its stake in shares of Gain Therapeutics by 15.6% in the fourth quarter. Geode Capital Management LLC now owns 397,942 shares of the company’s stock valued at $1,282,000 after buying an additional 53,796 shares in the last quarter. Jane Street Group LLC raised its holdings in shares of Gain Therapeutics by 234.5% in the fourth quarter. Jane Street Group LLC now owns 242,328 shares of the company’s stock valued at $780,000 after buying an additional 169,878 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Gain Therapeutics by 72.9% in the fourth quarter. State Street Corp now owns 157,537 shares of the company’s stock valued at $507,000 after buying an additional 66,400 shares during the last quarter. Institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Price Performance

Gain Therapeutics stock opened at $2.04 on Tuesday. The business’s 50-day simple moving average is $1.81 and its 200 day simple moving average is $1.93. The company has a quick ratio of 4.36, a current ratio of 4.36 and a debt-to-equity ratio of 0.02. The stock has a market cap of $89.03 million, a price-to-earnings ratio of -4.08 and a beta of 0.19. Gain Therapeutics, Inc. has a 12-month low of $1.53 and a 12-month high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.14) by $0.03. As a group, research analysts anticipate that Gain Therapeutics, Inc. will post -0.52 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on GANX. BTIG Research reiterated a “buy” rating and set a $5.00 price target on shares of Gain Therapeutics in a research report on Tuesday, August 11th. Roth Capital restated a “buy” rating on shares of Gain Therapeutics in a research report on Tuesday, May 12th. Weiss Ratings downgraded shares of Gain Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 9th. HC Wainwright reiterated a “buy” rating and set a $8.00 target price on shares of Gain Therapeutics in a research report on Wednesday, July 1st. Finally, Oppenheimer reiterated an “outperform” rating on shares of Gain Therapeutics in a research report on Wednesday, May 27th. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $7.50.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity.